Skip to main content
main-content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 8/2022

02.07.2022 | Original Article

Fusidic acid in a tertiary hospital: an observational study focusing on prescriptions, tolerance and susceptibility of Staphylococcus and Cutibacterium spp. strains from bone samples

verfasst von: Juliette Romaru, Anne Limelette, Delphine Lebrun, Morgane Bonnet, Véronique Vernet Garnier, Yohan N’Guyen

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Adverse drug reactions of broad-spectrum fluoroquinolones or rifampicin are not uncommon during osteomyelitis and orthopaedic implant infections (OOII). Thus, we made an overview (i) of the prescription of fusidic acid (FA) and (ii) of FA susceptibility of Staphylococcus sp. and Cutibacterium sp. strains isolated from bone samples. All prescriptions of FA and all bone samples with positive culture for Staphylococcus sp. or Cutibacterium sp. (Reims University Hospital June 2017–May 2021) were included. All Staphylococcus aureus strains were considered as significant, whereas Coagulase-negative Staphylococcus and Cutibacterium spp. strains were not if these strains grew only on one sole sample. The antibiotic susceptibility of Staphylococcus sp. strains and the susceptibility to FA of Cutibacterium sp. strains had been determined using disk diffusion methods, as described for Staphylococcus sp. in the CASFM/EUCAST guidelines. The mean FA consumption was 0.6 daily defined doses/1000 patient days. FA was prescribed for OOII due to Staphylococcus sp. and Cutibacterium sp. in 24 and 2 cases, respectively. Among 401 Staphylococcus sp. strains, there were 254 S. aureus (63.3%), 84 methicillin-resistant (20.9%) and 333 FA-susceptible (83.0%) strains. S. aureus and methicillin-sensitive strains were more likely to be susceptible to FA (p < 0.001). Among 39 Cutibacterium sp. strains, the FA inhibition zone diameter geometric mean was 28.6 mm (24–35 mm), suggesting that all these strains could be considered as susceptible to FA. These data suggested that FA could be more frequently used in OOII due to Staphylococcus sp. and Cutibacterium sp., subject to the absence of other resistant bacteria.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Drago L, De Vecchi E, Bortolin M, Zagra L, Romanò CL, Cappelletti L (2017) Epidemiology and antibiotic resistance of late prosthetic knee and hip infections. J Arthroplasty 32(8):2496–2500 CrossRef Drago L, De Vecchi E, Bortolin M, Zagra L, Romanò CL, Cappelletti L (2017) Epidemiology and antibiotic resistance of late prosthetic knee and hip infections. J Arthroplasty 32(8):2496–2500 CrossRef
2.
Zurück zum Zitat Paharik AE, Schreiber HL 4th, Spaulding CN, Dodson KW, Hultgren SJ (2017) Narrowing the spectrum: the new frontier of precision antimicrobials. Genome Med 9(1):110 CrossRef Paharik AE, Schreiber HL 4th, Spaulding CN, Dodson KW, Hultgren SJ (2017) Narrowing the spectrum: the new frontier of precision antimicrobials. Genome Med 9(1):110 CrossRef
3.
Zurück zum Zitat Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E et al (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–95 CrossRef Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E et al (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–95 CrossRef
4.
Zurück zum Zitat (2009) Société de Pathologie Infectieuse de Langue Française (SPILF); Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT); Groupe de Pathologie Infectieuse Pédiatrique (GPIP); Société Française d'Anesthésie et de Réanimation (SFAR); Société Française de Chirurgie Orthopédique et Traumatologique (SOFCOT); Société Française d'Hygiène Hospitalière (SFHH) et al. Clinical practice recommendations. Osteoarticular infections on materials (prosthesis, implant, osteosynthesis. Med Mal Infect 39(11):815–63. (2009) Société de Pathologie Infectieuse de Langue Française (SPILF); Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT); Groupe de Pathologie Infectieuse Pédiatrique (GPIP); Société Française d'Anesthésie et de Réanimation (SFAR); Société Française de Chirurgie Orthopédique et Traumatologique (SOFCOT); Société Française d'Hygiène Hospitalière (SFHH) et al. Clinical practice recommendations. Osteoarticular infections on materials (prosthesis, implant, osteosynthesis. Med Mal Infect 39(11):815–63.
5.
Zurück zum Zitat Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56(1):e1–e25 CrossRef Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56(1):e1–e25 CrossRef
6.
Zurück zum Zitat Benkabouche M, Racloz G, Spechbach H, Lipsky BA, Gaspoz JM, Uçkay I (2019) Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial. J Antimicrob Chemother 74(8):2394–2399 CrossRef Benkabouche M, Racloz G, Spechbach H, Lipsky BA, Gaspoz JM, Uçkay I (2019) Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial. J Antimicrob Chemother 74(8):2394–2399 CrossRef
7.
Zurück zum Zitat Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE (1998) Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279(19):1537–41 CrossRef Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE (1998) Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279(19):1537–41 CrossRef
8.
Zurück zum Zitat Bernard A, Kermarrec G, Parize P, Caruba T, Bouvet A, Mainardi JL et al (2015) Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. J Infect 71(2):200–206 CrossRef Bernard A, Kermarrec G, Parize P, Caruba T, Bouvet A, Mainardi JL et al (2015) Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. J Infect 71(2):200–206 CrossRef
9.
Zurück zum Zitat Roblot F, Besnier JM, Giraudeau B, Simonnard N, Jonville-Bera AP, Coipeau P et al (2007) Lack of association between rifampicin plasma concentration and treatment-related side effects in osteoarticular infections. Fundam Clin Pharmacol 21:363–369 CrossRef Roblot F, Besnier JM, Giraudeau B, Simonnard N, Jonville-Bera AP, Coipeau P et al (2007) Lack of association between rifampicin plasma concentration and treatment-related side effects in osteoarticular infections. Fundam Clin Pharmacol 21:363–369 CrossRef
10.
Zurück zum Zitat Vollmer NJ, Rivera CG, Stevens RW, Oravec CP, Mara KC, Suh GA et al (2021) Safety and tolerability of fluoroquinolones in patients with staphylococcal periprosthetic Joint Infections. Clin Infect Dis 73(5):850–856 CrossRef Vollmer NJ, Rivera CG, Stevens RW, Oravec CP, Mara KC, Suh GA et al (2021) Safety and tolerability of fluoroquinolones in patients with staphylococcal periprosthetic Joint Infections. Clin Infect Dis 73(5):850–856 CrossRef
11.
Zurück zum Zitat Mendes-Bastos P, Macedo R, Duarte R (2017) Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? Br J Dermatol 177:e150–e151 CrossRef Mendes-Bastos P, Macedo R, Duarte R (2017) Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? Br J Dermatol 177:e150–e151 CrossRef
12.
Zurück zum Zitat Jones RN, Mendes RE, Sader HS, Castanheira M (2011) In vitro antimicrobial findings for fusidic acid tested against contemporary (2008–2009) gram-positive organisms collected in the United States. Clin Infect Dis 52(Suppl 7):S477–S486 CrossRef Jones RN, Mendes RE, Sader HS, Castanheira M (2011) In vitro antimicrobial findings for fusidic acid tested against contemporary (2008–2009) gram-positive organisms collected in the United States. Clin Infect Dis 52(Suppl 7):S477–S486 CrossRef
13.
Zurück zum Zitat Curbete MM, Salgado HR (2016) A critical review of the properties of fusidic acid and analytical methods for its determination. Crit Rev Anal Chem 46(4):352–360 CrossRef Curbete MM, Salgado HR (2016) A critical review of the properties of fusidic acid and analytical methods for its determination. Crit Rev Anal Chem 46(4):352–360 CrossRef
14.
Zurück zum Zitat Minassian AM, Osmon DR, Berendt AR (2014) Clinical guidelines in the management of prosthetic joint infection. J Antimicrob Chemother 69(Suppl 1):i29-35 CrossRef Minassian AM, Osmon DR, Berendt AR (2014) Clinical guidelines in the management of prosthetic joint infection. J Antimicrob Chemother 69(Suppl 1):i29-35 CrossRef
15.
Zurück zum Zitat Klein S, Nurjadi D, Eigenbrod T, Bode KA (2016) Evaluation of antibiotic resistance to orally administrable antibiotics in staphylococcal bone and joint infections in one of the largest university hospitals in Germany: is there a role for fusidic acid? Int J Antimicrob Agents 47(2):155–157 CrossRef Klein S, Nurjadi D, Eigenbrod T, Bode KA (2016) Evaluation of antibiotic resistance to orally administrable antibiotics in staphylococcal bone and joint infections in one of the largest university hospitals in Germany: is there a role for fusidic acid? Int J Antimicrob Agents 47(2):155–157 CrossRef
17.
Zurück zum Zitat Biswas M, Owen K, Jones MK (2002) Hypocalcaemia during fusidic acid therapy. J R Soc Med 95(2):91–93 CrossRef Biswas M, Owen K, Jones MK (2002) Hypocalcaemia during fusidic acid therapy. J R Soc Med 95(2):91–93 CrossRef
18.
Zurück zum Zitat Bataillard M, Beyens MN, Mounier G, Vergnon-Miszczycha D, Bagheri H, Cathebras P (2019) Muscle damage due to fusidic acid-statin interaction: review of 75 cases from the French pharmacovigilance database and literature reports. Am J Ther 26(3):e375–e379 CrossRef Bataillard M, Beyens MN, Mounier G, Vergnon-Miszczycha D, Bagheri H, Cathebras P (2019) Muscle damage due to fusidic acid-statin interaction: review of 75 cases from the French pharmacovigilance database and literature reports. Am J Ther 26(3):e375–e379 CrossRef
19.
Zurück zum Zitat Farrell DJ, Castanheira M, Chopra I (2011) Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 52(Suppl 7):S487-92 CrossRef Farrell DJ, Castanheira M, Chopra I (2011) Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 52(Suppl 7):S487-92 CrossRef
20.
Zurück zum Zitat Pushkin R, Iglesias-Ussel MD, Keedy K, MacLauchlin C, Mould DR, Berkowitz R et al (2016) A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: a newly identified drug-drug interaction. Clin Infect Dis 63(12):1599–1604 CrossRef Pushkin R, Iglesias-Ussel MD, Keedy K, MacLauchlin C, Mould DR, Berkowitz R et al (2016) A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: a newly identified drug-drug interaction. Clin Infect Dis 63(12):1599–1604 CrossRef
21.
Zurück zum Zitat Ertek M, Yazgi H, Erol S, Altoparlak U (2002) Demonstration of in vitro antagonism between fusidic acid and quinolones. J Int Med Res 30(5):525–528 CrossRef Ertek M, Yazgi H, Erol S, Altoparlak U (2002) Demonstration of in vitro antagonism between fusidic acid and quinolones. J Int Med Res 30(5):525–528 CrossRef
22.
Zurück zum Zitat Siala W, Rodriguez-Villalobos H, Fernandes P, Tulkens PM, Van Bambeke F (2018) Activities of combinations of antistaphylococcal antibiotics with fusidic acid against staphylococcal biofilms in in vitro static and dynamic models. Antimicrob Agents Chemother 62(7):e00598-e618 CrossRef Siala W, Rodriguez-Villalobos H, Fernandes P, Tulkens PM, Van Bambeke F (2018) Activities of combinations of antistaphylococcal antibiotics with fusidic acid against staphylococcal biofilms in in vitro static and dynamic models. Antimicrob Agents Chemother 62(7):e00598-e618 CrossRef
23.
Zurück zum Zitat Hajikhani B, Goudarzi M, Kakavandi S, Amini S, Zamani S, van Belkum A et al (2021) The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis. Antimicrob Resist Infect Control 10(1):75 CrossRef Hajikhani B, Goudarzi M, Kakavandi S, Amini S, Zamani S, van Belkum A et al (2021) The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis. Antimicrob Resist Infect Control 10(1):75 CrossRef
24.
Zurück zum Zitat Fink B, Sevelda F (2017) Periprosthetic joint infection of shoulder arthroplasties: diagnostic and treatment options. Biomed Res Int 2017:4582756 CrossRef Fink B, Sevelda F (2017) Periprosthetic joint infection of shoulder arthroplasties: diagnostic and treatment options. Biomed Res Int 2017:4582756 CrossRef
25.
Zurück zum Zitat Boisrenoult P (2018) Cutibacterium acnes prosthetic joint infection: diagnosis and treatment. Orthop Traumatol Surg Res 104(1S):S19–S24 CrossRef Boisrenoult P (2018) Cutibacterium acnes prosthetic joint infection: diagnosis and treatment. Orthop Traumatol Surg Res 104(1S):S19–S24 CrossRef
26.
Zurück zum Zitat Hedlundh U, Zacharatos M, Magnusson J, Gottlander M, Karlsson J (2021) Periprosthetic hip infections in a Swedish regional hospital between 2012 and 2018: is there a relationship between Cutibacterium acnes infections and uncemented prostheses? J Bone Jt Infect 6(6):219–228 CrossRef Hedlundh U, Zacharatos M, Magnusson J, Gottlander M, Karlsson J (2021) Periprosthetic hip infections in a Swedish regional hospital between 2012 and 2018: is there a relationship between Cutibacterium acnes infections and uncemented prostheses? J Bone Jt Infect 6(6):219–228 CrossRef
27.
Zurück zum Zitat Faber M, Rosdahl VT (1990) Susceptibility to fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemother 25(Suppl B):7–14 CrossRef Faber M, Rosdahl VT (1990) Susceptibility to fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemother 25(Suppl B):7–14 CrossRef
28.
Zurück zum Zitat Bernard L, Arvieux C, Brunschweiler B, Touchais S, Ansart S, Bru JP et al (2021) Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med 384(21):1991–2001 CrossRef Bernard L, Arvieux C, Brunschweiler B, Touchais S, Ansart S, Bru JP et al (2021) Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med 384(21):1991–2001 CrossRef
Metadaten
Titel
Fusidic acid in a tertiary hospital: an observational study focusing on prescriptions, tolerance and susceptibility of Staphylococcus and Cutibacterium spp. strains from bone samples
verfasst von
Juliette Romaru
Anne Limelette
Delphine Lebrun
Morgane Bonnet
Véronique Vernet Garnier
Yohan N’Guyen
Publikationsdatum
02.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 8/2022
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-022-04469-6

Weitere Artikel der Ausgabe 8/2022

European Journal of Clinical Microbiology & Infectious Diseases 8/2022 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.